Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM - Nauck, M. A.; Wollschläger, D.; Werner, J.; Holst, J. J.; Ørskov, C.; Creutzfeldt, W.; Willms, B. (Springer, 1996)
http://dx.doi.org/10.1007/s001250050613
Keywords: WW-YZ